ACTRN12615000539538已完成未知
Feasibility study of the Drug Burden Index with Home Medicine Review in older Australians
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Educational / counselling / training
入排标准
- 年龄范围
- 65 Years 至 o limit（—）
- 性别
- All
入选标准
- •Pharmacists
- •*Current registered Australian pharmacist
- •*Current accreditation to conduct HMRs
- •*Have conducted at least 10 HMRs in the last 1-2 years
- •*Will be able to complete 10 HMRs in the next 3 months
- •*Able to attend an information day at University of Sydney
- •*Aged greater than or equal to 65 years
- •*Can speak English and is able to conduct a telephone interview
- •*Eligible for a HMR
- •*Able to provide informed written consent (Patient or carer)
排除标准
- •unable to obtain informed consent from pharmacists or patients
研究者
相似试验
已完成
不适用
Anticholinergic and sedative drug use and functional status among older Australians.ACTRN12608000018314Geoff & Elaine Penney Aged Care Trust Fund150
已完成
不适用
Decreasing the load? The Drug Burden Index - A tool for medication reviews in older peoplepolyfarmacie, anticholinerge- en sedatieve bijwerkingenpolypharmacyuse of more than 5 medications at the same timeNL-OMON40924Rijksuniversiteit Groningen240
尚未招募
不适用
Out of pocket expenditure,OOPE, head neck cancer.CTRI/2019/11/021947TATA MEMORIAL HOSPITA
进行中（未招募）
1 期
Feasibility study to assess safety of high dose of lanreotide in net patients poorly controlled by standard doses of SSAeuroendocrine tumoursMedDRA version: 14.1Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005222-30-ITIVERSITA' DI GENOVA
尚未招募
不适用
Study on Safety and Cost Calculation of DPP-IV inhibitor Use in Type 2 Diabetic PatientsCTRI/2022/01/039294Dr TMA PAI FELLOWSHIP MAHE MANIPA